The Tsetis Group of Pharmaceutical Companies (OFET) turns 60 years old this year and consists of the pharmaceutical industries UNI-PHARMA & INTERMED, the commercial company Pharmabelle in Cyprus and the modern plant extraction unit UNI-HERBO. UNI-PHARMA and INTERMED lead the domestic & international market with a variety of brands, in the field of pharmaceutical products, nutritional supplements, medical devices and dermocosmetic products.
UNI-PHARMA is one of the leading greek pharmaceutical industries with continuous activity for 60 years, which researches, develops, produces and distributes pharmaceutical products, nutritional supplements and medical devices products of high quality, efficacy and safety, both in the domestic market and in dynamically developing foreign markets (export activity in 60 countries worldwide). Some of the dominant products of the company are SALOSPIR®, T4®, TREBON®, TROFOCARD®, APOTEL® etc. It ranks first in Greece in annual tablet production, with a production capacity of 2 billion tablets and 50 million injectable units annually. Its capacity was expanded in 2015 with the construction of the new facilities, while the first factory was completely renovated/upgraded in 2020. The two facilities are a model of bioclimatic application in full harmony with the natural environment. Also, UNI-PHARMA follows a strong Intellectual Property strategy, having historically granted over 100 patents.
InterMed was founded in 1996 by Kleon Tsetis, a pharmacist who envisioned a pioneer manufacturing industry in the medical field, which would contribute to the treatment of everyday needs as well as specific health issues that affect modern humans. During the years of its operation, InterMed has demonstrated a continuing upward course, focusing on exploring future prospects with regards to international scientific developments and constantly expanding its product portfolio, which is prominent for the innovation and quality. The result of this course has been the establishment of InterMed in the Greek and International markets with brands such as Unisept®, Chlorhexil®, Eva®, Reval®, Algofren® etc.
OFET’s strategic planning remains stable with the main axes emphasizing on Research & Development, Innovation, Responsibility, Solidarity, Business Ethics and dedication to Excellence. OFET invests dynamically in modern production units and advanced technologies, in active people with high qualifications and ethics, in organizational systems that ensure responsibility and participation and also in collaborations with academic institutions. OFET continuously develops strategic collaborations with greek Universities and Research Institutes by financing research projects from its own funds, while it has previous experience in research projects co-financed by Greece and the European Union, as an industrial partner with own funding. During its years of operation, OFET has received several awards for business excellence.